North Star Cancer Research Foundation launched a fundraising campaign to raise $100,000 in October 2025 to fund critical research by Dr. David Shapiro and Dr. Paul Hergenrother at University of Illinois.

This research focuses on the drug TEQ103 in combination with NK-92, a type of immune system cell that can be given as a cancer immunotherapy in clinical trials, representing a potential breakthrough treatment for metastatic breast cancer (MBC).

Metastatic Breast Cancer has proven very difficult to treat because cancer cells continue to adapt and become resistant to targeted treatments and chemotherapies. TEQ103 uniquely stimulates a response by Natural Killer cells and this combination therapy may prevent resistant cancer cells from escaping destruction.

With federal cancer research funding being slashed, outside support is urgently needed to keep advancing this work.

Join Us On The Journey